PC
SGMO

Polar Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Polar Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-36,159
Closed -$401K – 285
2015
Q2 		$401K Buy
36,159
+1,833
+5% +$23.6K 0.01% 273
2015
Q1 		$538K Buy
+34,326
New +$531K 0.01% 267

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Polar Capital's SGMO Position: Q3 2015 in Review

Polar Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2015, closing a stake of 36,159 shares — an estimated $401K sold.

Polar Capital first reported a position in SGMO in Q1 2015 and held it in 2 quarters. The position peaked at $538K in Q1 2015. 141 funds tracked by Wall St. Rank hold SGMO as of Q3 2015.

  • Polar Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2015 after selling out during the quarter.
  • Polar Capital sold 36,159 SANGAMO THERAPEUTICS INC shares in Q3 2015, an estimated $401K.
  • Polar Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2015 and held it in 2 quarters.
  • Polar Capital's SANGAMO THERAPEUTICS INC position peaked at $538K in Q1 2015.
  • 141 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2015.

Based on Polar Capital's 13F filing for Q3 2015, filed 16 Nov 2015.